[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL3334744T3 - Kompleksy pierścienia makrocyklicznego pentaaza posiadające biodostępność po podaniu doustnym - Google Patents

Kompleksy pierścienia makrocyklicznego pentaaza posiadające biodostępność po podaniu doustnym

Info

Publication number
PL3334744T3
PL3334744T3 PL16835928T PL16835928T PL3334744T3 PL 3334744 T3 PL3334744 T3 PL 3334744T3 PL 16835928 T PL16835928 T PL 16835928T PL 16835928 T PL16835928 T PL 16835928T PL 3334744 T3 PL3334744 T3 PL 3334744T3
Authority
PL
Poland
Prior art keywords
oral bioavailability
macrocyclic ring
pentaaza macrocyclic
ring complexes
complexes possessing
Prior art date
Application number
PL16835928T
Other languages
English (en)
Inventor
Jeffery L. Keene
Otto F. Schall
Dennis P. Riley
Original Assignee
Galera Labs, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galera Labs, Llc filed Critical Galera Labs, Llc
Publication of PL3334744T3 publication Critical patent/PL3334744T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/08—Copper compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds
    • C07F15/025—Iron compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/04—Nickel compounds
    • C07F15/045—Nickel compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL16835928T 2015-08-11 2016-08-11 Kompleksy pierścienia makrocyklicznego pentaaza posiadające biodostępność po podaniu doustnym PL3334744T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562203761P 2015-08-11 2015-08-11
PCT/US2016/046599 WO2017027728A1 (en) 2015-08-11 2016-08-11 Pentaaza macrocyclic ring complexes possessing oral bioavailability
EP16835928.9A EP3334744B1 (en) 2015-08-11 2016-08-11 Pentaaza macrocyclic ring complexes possessing oral bioavailability

Publications (1)

Publication Number Publication Date
PL3334744T3 true PL3334744T3 (pl) 2020-09-21

Family

ID=57984526

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16835928T PL3334744T3 (pl) 2015-08-11 2016-08-11 Kompleksy pierścienia makrocyklicznego pentaaza posiadające biodostępność po podaniu doustnym

Country Status (30)

Country Link
US (5) US10597415B2 (pl)
EP (2) EP3334744B1 (pl)
JP (3) JP7041959B2 (pl)
KR (1) KR20180064380A (pl)
CN (3) CN113416170A (pl)
AU (3) AU2016306568B2 (pl)
CA (1) CA2994845A1 (pl)
CL (1) CL2018000371A1 (pl)
CO (1) CO2018002544A2 (pl)
CY (1) CY1123960T1 (pl)
DK (1) DK3334744T3 (pl)
EA (1) EA201890471A1 (pl)
ES (1) ES2807528T3 (pl)
HK (1) HK1257313A1 (pl)
HR (1) HRP20201092T1 (pl)
HU (1) HUE049926T2 (pl)
IL (3) IL297735B2 (pl)
LT (1) LT3334744T (pl)
MX (2) MX2018001605A (pl)
MY (1) MY196401A (pl)
NZ (1) NZ740359A (pl)
PH (1) PH12018500296A1 (pl)
PL (1) PL3334744T3 (pl)
PT (1) PT3334744T (pl)
RS (1) RS60558B1 (pl)
SG (1) SG10202002859QA (pl)
SI (1) SI3334744T1 (pl)
UA (1) UA126788C2 (pl)
WO (1) WO2017027728A1 (pl)
ZA (2) ZA201801546B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9855279B2 (en) 2006-10-12 2018-01-02 Galera Labs, Llc Methods of treating oral mucositis
CN111467351A (zh) 2011-09-26 2020-07-31 加莱拉实验室有限责任公司 用于治疗疾病的方法
EP3334744B1 (en) 2015-08-11 2020-04-22 Galera Labs, LLC Pentaaza macrocyclic ring complexes possessing oral bioavailability
US11219614B2 (en) 2016-09-01 2022-01-11 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
US20210361701A1 (en) 2017-02-15 2021-11-25 Galera Labs, Llc Pentaaza macrocyclic ring complexes for local delivery
AU2018252003A1 (en) * 2017-04-13 2019-11-21 Galera Labs, Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
EP3388082A1 (en) * 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
EA201992431A1 (ru) 2017-10-13 2020-03-13 ГАЛЕРА ЛЭБЗ, ЭлЭлСи Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса
IL291989A (en) * 2019-10-10 2022-06-01 Galera Labs Llc Production method for an aqueous formulation of a manganese-containing coordination complex, formulation and treatment method

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001212A (en) 1973-10-03 1977-01-04 E. I. Du Pont De Nemours And Company Macrocyclic polyamines
US3930867A (en) 1974-01-07 1976-01-06 E. I. Du Pont De Nemours And Company Macrocyclic polyamines as sensitizers for silver halide emulsions
JPS61226751A (ja) 1985-03-30 1986-10-08 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料用処理液及びその処理方法
US5096724A (en) 1988-06-03 1992-03-17 Aquanautics Corporation Methods, compositions, and systems for ligand extraction
GB9001245D0 (en) 1990-01-19 1990-03-21 Salutar Inc Compounds
ATE164164T1 (de) * 1991-07-19 1998-04-15 Monsanto Co Mangan-komplexe mit stickstoff enthaltenden makrozyklischen liganden, wirksam als superoxiddismutasekatalysatoren.
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
WO1995028968A1 (en) 1994-04-22 1995-11-02 Monsanto Company Diagnostic image analysis with metal complexes
US6245758B1 (en) 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
JPH0840941A (ja) 1994-07-29 1996-02-13 Kanegafuchi Chem Ind Co Ltd 炎症性腸疾患治療製剤
US6525041B1 (en) 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
EP0846003A1 (en) 1995-08-17 1998-06-10 Monsanto Company Methods of diagnostic image analysis using bioconjugates of metal complexes of nitrogen-containing macrocyclic ligands
EP0844889A1 (en) 1995-08-17 1998-06-03 Monsanto Company Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands
US20050171198A1 (en) 1997-06-20 2005-08-04 Metaphore Pharmaceuticals, Inc. SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6180620B1 (en) 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
US20020128248A1 (en) 1997-06-20 2002-09-12 Metaphore Pharmaceuticals, Inc SODm therapy for prevention and/or treatment of inflammatory disease
US20060270639A1 (en) 1997-06-20 2006-11-30 Daniela Salvemini Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
JP2991172B2 (ja) 1997-10-24 1999-12-20 日本電気株式会社 半導体装置
AU737650B2 (en) 1997-11-03 2001-08-23 Duke University Substituted porphyrins
GB9817845D0 (en) 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
US6040330A (en) 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
DE60018925T2 (de) 1999-05-27 2006-04-13 Pharmacia Corp.(N.D.Ges.D.Staates Delaware) Biomaterialien, modifiziert mit superoxid-dismutase imitatoren
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
JP2003502372A (ja) 1999-06-23 2003-01-21 エリック・エフ・バーンスタイン 創傷治癒および光傷害の防止におけるニトロキシドの使用
US6552010B1 (en) 1999-11-12 2003-04-22 Genelabs Technologies, Inc. Treatment of SLE with dehydroepiandrosterone
AU3679801A (en) 2000-02-08 2001-08-20 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
JP2004507487A (ja) 2000-08-29 2004-03-11 メファ・アクチェンゲゼルシャフト 腸疾患治療薬
US7166910B2 (en) 2000-11-28 2007-01-23 Knowles Electronics Llc Miniature silicon condenser microphone
US20020072512A1 (en) 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
AU2002241807A1 (en) 2001-01-05 2002-07-16 Metaphore Pharmaceuticals, Inc. Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
DE60233317D1 (de) 2001-01-19 2009-09-24 Nat Jewish Med & Res Center Medikament zum schutz in der radiotherapie
WO2002058686A2 (en) 2001-01-26 2002-08-01 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
US20040137638A1 (en) 2002-03-04 2004-07-15 Slomczynska Urszula J. Chromatography of metal complexes
CA2439971A1 (en) 2001-03-02 2002-09-12 Metaphore Pharmaceuticals, Inc. Chromatography of metal complexes
WO2002100395A1 (en) 2001-06-08 2002-12-19 Genzyme Corporation Bismuth salts of anti-oxidants and radical scavengers for prevention and treatment of mucous membrane ulcers
US20040132706A1 (en) 2001-10-05 2004-07-08 Daniela Salvemini Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension
RU2313368C2 (ru) 2001-11-01 2007-12-27 Ю Эй Би Рисерч Фаундейшн Комбинации антител, обладающих селективностью по отношению к рецептору лиганда, индуцирующему апоптоз, ассоциированный с фактором некроза опухоли, и других терапевтических средств
JP2005530738A (ja) 2002-04-16 2005-10-13 アイシス・イノヴェイション・リミテッド 組織障害の予防及び／又は治療のためのクルクミン
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
US6781231B2 (en) 2002-09-10 2004-08-24 Knowles Electronics Llc Microelectromechanical system package with environmental and interference shield
US6798047B1 (en) 2002-12-26 2004-09-28 Amkor Technology, Inc. Pre-molded leadframe
WO2005042718A2 (en) 2003-10-31 2005-05-12 Metaphore Pharmaceuticals, Inc. Compositions and methods for treating, preventing, reversing and inhibiting pain
FR2863892B1 (fr) 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
WO2005070126A2 (en) 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
MXPA06011244A (es) 2004-03-29 2007-04-13 Inotek Pharmaceuticals Corp Compuestos de porfirina sustituida por piridilo, y metodos de uso de los mismos.
GB0412893D0 (en) * 2004-06-10 2004-07-14 Univ Hull Novel antiviral macrocycle derivatives and metal complexes, incorporating bridged macrocycles
US7262498B2 (en) 2004-10-19 2007-08-28 Hewlett-Packard Development Company, L.P. Assembly with a ring and bonding pads formed of a same material on a substrate
US20070148154A1 (en) 2004-12-17 2007-06-28 Universite Rene Descartes (Paris V) Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs
US8217166B2 (en) 2005-05-05 2012-07-10 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
WO2006083508A2 (en) 2005-01-10 2006-08-10 Metaphore Pharmaceuticals Inc. Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
WO2006078713A2 (en) 2005-01-19 2006-07-27 Metaphore Pharmaceuticals, Inc. Methotrexate combinations for treating inflammatory diseases
EP1863778B1 (en) 2005-03-31 2015-12-30 Merck Sharp & Dohme Corp. Spirocyclic thrombin receptor antagonists
CN2870352Y (zh) 2005-12-23 2007-02-14 瑞声声学科技(深圳)有限公司 微机电系统传声器扣合式封装结构
WO2007139897A1 (en) 2006-05-23 2007-12-06 University Of Utah Research Foundation Compositions and methods for the inhibition of endothelial nitric oxide synthase activity
WO2008027547A2 (en) 2006-08-31 2008-03-06 The Brigham And Women's Hospital, Inc. Antioxidant therapies
WO2008033466A2 (en) 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
US9855279B2 (en) 2006-10-12 2018-01-02 Galera Labs, Llc Methods of treating oral mucositis
TWI333264B (en) 2007-01-10 2010-11-11 Advanced Semiconductor Eng Packaging structure and method of mems microphone
US8486928B2 (en) * 2007-11-14 2013-07-16 Galera Therapeutics Super-oxide dismutase mimetics
WO2009111294A1 (en) 2008-02-29 2009-09-11 Eagle Pharmaceuticals, Inc. Topotecan ready to use solutions
AU2009241514A1 (en) 2008-04-15 2009-11-05 Intermune, Inc. Novel inhibitors of hepatitis C virus replication
CA2724550C (en) 2008-05-22 2017-01-03 Kereos, Inc. Combination antitumor therapy
US8642557B2 (en) 2010-03-12 2014-02-04 Abbvie Biotherapeutics Inc. CTLA4 proteins and their uses
US20120207687A1 (en) 2011-01-14 2012-08-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Topical formulations of targeted nitroxide agents
CN111467351A (zh) 2011-09-26 2020-07-31 加莱拉实验室有限责任公司 用于治疗疾病的方法
US9238659B2 (en) 2012-11-19 2016-01-19 The University Of Hong Kong Method of using binuclear gold (I) compounds for cancer treatment
EP3334744B1 (en) 2015-08-11 2020-04-22 Galera Labs, LLC Pentaaza macrocyclic ring complexes possessing oral bioavailability
WO2017025496A1 (en) 2015-08-12 2017-02-16 Bayer Pharma Aktiengesellschaft Pharmaceutical combination for the treatment of cancer
KR20180132939A (ko) 2016-05-03 2018-12-12 갈레라 랩스, 엘엘씨 암 치료를 위한 조합 요법
US11219614B2 (en) 2016-09-01 2022-01-11 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
WO2018125862A1 (en) 2016-12-27 2018-07-05 Soon Kap Hahn Prevention of local tumor recurrence following surgery using sustained and/or delayed release of medicaments contained in micro-particles
US20210361701A1 (en) 2017-02-15 2021-11-25 Galera Labs, Llc Pentaaza macrocyclic ring complexes for local delivery
AU2018252003A1 (en) 2017-04-13 2019-11-21 Galera Labs, Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
EA201992431A1 (ru) 2017-10-13 2020-03-13 ГАЛЕРА ЛЭБЗ, ЭлЭлСи Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса
WO2019152661A1 (en) 2018-01-31 2019-08-08 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent

Also Published As

Publication number Publication date
CN113416170A (zh) 2021-09-21
CA2994845A1 (en) 2017-02-16
US20180237462A1 (en) 2018-08-23
WO2017027728A9 (en) 2017-04-06
IL297735B2 (en) 2024-08-01
UA126788C2 (uk) 2023-02-08
US20170044193A1 (en) 2017-02-16
IL257346A (en) 2018-03-29
LT3334744T (lt) 2020-07-27
ES2807528T3 (es) 2021-02-23
US9738670B2 (en) 2017-08-22
US20210347796A1 (en) 2021-11-11
AU2023200738A1 (en) 2023-03-09
NZ740359A (en) 2024-07-05
AU2016306568B2 (en) 2021-01-07
IL297735B1 (en) 2024-04-01
KR20180064380A (ko) 2018-06-14
DK3334744T3 (da) 2020-07-27
CO2018002544A2 (es) 2018-07-10
SG10202002859QA (en) 2020-05-28
CN108350009B (zh) 2021-07-09
PT3334744T (pt) 2020-07-28
HUE049926T2 (hu) 2020-11-30
US10597415B2 (en) 2020-03-24
IL257346B (en) 2021-12-01
JP2022023183A (ja) 2022-02-07
IL287546B (en) 2022-12-01
CY1123960T1 (el) 2022-03-24
IL287546A (en) 2021-12-01
AU2020289730B2 (en) 2022-11-10
HK1257313A1 (zh) 2019-10-18
US11066433B2 (en) 2021-07-20
CL2018000371A1 (es) 2018-08-03
EP3334744A4 (en) 2019-03-06
MX2022010230A (es) 2022-09-19
US20200223879A1 (en) 2020-07-16
AU2020289730A1 (en) 2021-01-21
JP2018525388A (ja) 2018-09-06
IL297735A (en) 2022-12-01
PH12018500296A1 (en) 2018-08-13
ZA201801546B (en) 2020-07-29
AU2016306568A1 (en) 2018-03-22
US9738669B2 (en) 2017-08-22
EP3738967A1 (en) 2020-11-18
US20170042907A1 (en) 2017-02-16
JP2024012401A (ja) 2024-01-30
SI3334744T1 (sl) 2020-10-30
US12077549B2 (en) 2024-09-03
EP3334744A1 (en) 2018-06-20
ZA202001373B (en) 2021-10-27
HRP20201092T1 (hr) 2020-10-30
JP7041959B2 (ja) 2022-03-25
EA201890471A1 (ru) 2018-10-31
RS60558B1 (sr) 2020-08-31
EP3334744B1 (en) 2020-04-22
MY196401A (en) 2023-03-29
WO2017027728A1 (en) 2017-02-16
CN108350009A (zh) 2018-07-31
MX2018001605A (es) 2018-09-26
CN113402560A (zh) 2021-09-17
IL287546B2 (en) 2023-04-01

Similar Documents

Publication Publication Date Title
IL287546A (en) Macrocyclic ring pentase complexes with oral bioavailability
AU365267S (en) Ring
TWD174460S (zh) 戒指
GB201612092D0 (en) Pharmaceutical compounds
GB2532789B (en) Absolute rotary encoder
ZA201607765B (en) Novel macrocyclic compounds
GB201512967D0 (en) Rotary encoder
IL256205B (en) Positional encoder
EP3382222A4 (en) ROTATION RING
EP3338805A4 (en) Drug complex
GB201602090D0 (en) Powder
HK1210657A2 (en) Ring sizer
GB2550216B (en) Teething Ring
GB201615916D0 (en) Pharmaceutical compound
GB201615912D0 (en) Pharmaceutical compound
GB201715210D0 (en) Macrocyclic compounds
AU201812909S (en) Ring
GB201704125D0 (en) Macrocyclic Compounds
GB201704121D0 (en) Macrocyclic compounds
GB201720326D0 (en) Nimb Ring
AU201715228S (en) Ring
AU201715227S (en) Ring
AU201613163S (en) Ring
TWM533982U (en) Rotary bed structure
GB201602871D0 (en) Pharmaceutical compounds